Centers for American Indian and Alaska Native Health.
Department of Health Systems Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora.
Med Care. 2021 Jun 1;59(6):477-486. doi: 10.1097/MLR.0000000000001521.
The burden of diabetes is exceptionally high among American Indian and Alaska Native (AI/AN) peoples. The Indian Health Service (IHS) and Tribal health programs provide education, case management, and advanced practice pharmacy (ECP) services for AI/ANs with diabetes to improve their health outcomes.
The objective of this study was to evaluate patient outcomes associated with ECP use by AI/AN adults with diabetes.
This observational study included the analysis of IHS data for fiscal years (FY) 2011-2013. Using propensity score models, we assessed FY2013 patient outcomes associated with FY2012 ECP use, controlling for FY2011 baseline characteristics.
AI/AN adults with diabetes who used IHS and Tribal health services (n=28,578).
We compared health status and hospital utilization outcomes for ECP users and nonusers.
Among adults with diabetes, ECP users, compared with nonusers, had lower odds of high systolic blood pressure [odds ratio (OR)=0.85, P<0.001] and high low-density lipoprotein cholesterol (OR=0.89, P<0.01). Among adults with diabetes absent cardiovascular disease (CVD) at baseline, 3 or more ECP visits, compared with no visits, was associated with lower odds of CVD onset (OR=0.79, P<0.05). Among adults with diabetes and CVD, any ECP use was associated with lower odds of end-stage renal disease onset (OR=0.60, P<0.05). ECP users had lower odds of 1 or more hospitalizations (OR=0.80, P<0.001).
Findings on positive patient outcomes associated with ECP use by adults with diabetes may inform IHS and Tribal policies, funding, and enhancements to ECP services to reduce disparities between AI/ANs and other populations in diabetes-related morbidity and mortality.
糖尿病给美洲印第安人和阿拉斯加原住民(AI/AN)群体带来了巨大的负担。美国印第安人卫生服务局(IHS)和部落卫生计划为患有糖尿病的 AI/AN 提供教育、病例管理和高级实践药学(ECP)服务,以改善他们的健康结果。
本研究旨在评估 ECP 用于治疗 AI/AN 糖尿病患者的患者结局。
本观察性研究包括对 2011 财年至 2013 财年 IHS 数据的分析。使用倾向评分模型,我们评估了 2012 财年 ECP 使用与 2013 财年患者结局的关联,同时控制了 2011 财年的基线特征。
使用 IHS 和部落卫生服务的 AI/AN 成年糖尿病患者(n=28578)。
我们比较了 ECP 用户和非用户的健康状况和医院利用结果。
在患有糖尿病的成年人中,与非使用者相比,ECP 使用者发生高血压[比值比(OR)=0.85,P<0.001]和低高密度脂蛋白胆固醇(OR=0.89,P<0.01)的可能性较低。在基线无心血管疾病(CVD)的患有糖尿病的成年人中,与无就诊相比,就诊 3 次或更多次 ECP 与 CVD 发病的可能性较低(OR=0.79,P<0.05)。在患有糖尿病和 CVD 的成年人中,任何 ECP 使用均与较低的终末期肾病发病几率相关(OR=0.60,P<0.05)。ECP 使用者发生 1 次或更多次住院治疗的可能性较低(OR=0.80,P<0.001)。
这些发现表明,ECP 用于治疗糖尿病成年人的患者结局呈阳性,这可能为 IHS 和部落政策、资金以及 ECP 服务的增强提供信息,以减少 AI/AN 与其他人群在糖尿病相关发病率和死亡率方面的差异。